Skip to main
STAA
STAA logo

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 0%
Hold 38%
Sell 8%
Strong Sell 0%

Bulls say

Staar Surgical Co is positioned for continued growth as it anticipates a 7% year-over-year sales increase in 2026, building on a strong normalized base of $146 million in 2025, with expectations for share gains in the implantable Collamer lens market. Potential drivers of this positive outlook include the accelerated domestic launch of the EVO lens, increased market share within the refractive error correction segment, and improved profit margins leading to stronger earnings per share growth. The company's strategic initiatives, led by CEO Steve Farrell, aim to streamline operations and enhance cost structures, further solidifying its competitive edge in the global refractive market.

Bears say

Staar Surgical Co. faces a negative outlook due to several fundamental issues reflected in its financial performance metrics. The company's normalized adjusted EBITDA of $6.7 million was significantly impacted by a $27.5 million revenue decrease linked to high inventory levels with a new distributor in China, which raises concerns about both immediate results and future guidance. Additionally, potential risks associated with declining revenue in China, increased competition from lower-cost alternatives, and broader macroeconomic challenges further exacerbate the uncertainty surrounding Staar's financial stability and growth prospects.

STAAR Surgical (STAA) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 0% recommend Buy, 38% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Buy based on their latest research and market trends.

According to 13 analysts, STAAR Surgical (STAA) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.